Effects of antiviral treatment on influenza-related complications over four influenza seasons: 2006–2010

References

• Thompson MG, Shay DK, Zhou H, et al. Estimates of Deaths Associated With Seasonal Influenza – United States, 1976–2007 (Reprinted from MMWR, vol 59, pg 1057-1062, 2010). JAMA 2010;304:1778–80
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (C.D.C.). Seasonal Influenza (Flu) – People at High Risk of Developing Flu-Related Complications. 2011. http://www.cdc.gov/flu/about/disease/high_risk.htm
   Google Scholar
• Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59:1–62
   PubMedGoogle Scholar
• Irwin DE, Weatherby LB, Huang WY, et al. Impact of patient characteristics on the risk of influenza/ILI-related complications. BMC Health Serv Res 2001;1:8
   PubMed Web of Science ®Google Scholar
• World Health Organization (W.H.O.). Pandemic (H1N1) 2009 – update 112. 2009. http://www.who.int/csr/don/2010_08_06/en/
   Google Scholar
• N Principi, S Esposito, R Gasparini, et al. Burden of influenza in healthy children and their households. Arch Dis Child 2004;89:1002–7
   Google Scholar
• Glezen WP. How did the 2008–2009 seasonal influenza vaccine affect the pandemic? Clin Infect Dis 2010;51:1380–2
   PubMed Web of Science ®Google Scholar
• Monto AS. Individual and community impact of influenza. Pharmacoeconomics 1999;16(Suppl 1):1–6
   PubMed Web of Science ®Google Scholar
• Szucs TD. Medical economics in the field of influenza – past, present and future. Virus Res 2004;103:25–30
   PubMed Web of Science ®Google Scholar
• World Health Organization (W.H.O.). Summary report of a High-Level Consultation: New Influenza A (H1N1). Geneva: W.H.O., 2009
   Google Scholar
• Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond) 1998;48:85–90
   PubMed Web of Science ®Google Scholar
• Ng TP, Pwee KH, Niti M, Goh LG. Influenza in Singapore: assessing the burden of illness in the community. Ann Acad Med Singapore 2002;31:182–8
   PubMed Web of Science ®Google Scholar
• Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003;51:123–9
   PubMed Web of Science ®Google Scholar
• Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000;19:410–17
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355:1845–50
   PubMed Web of Science ®Google Scholar
• The M.I.S.T. (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998;352:1877–81
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127–33
   PubMed Web of Science ®Google Scholar
• Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667–72
   PubMed Web of Science ®Google Scholar
• Hernan MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011;53:277–9
   PubMed Web of Science ®Google Scholar
• Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235
   PubMed Web of Science ®Google Scholar
• Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. Med Gen Med 2007;9:23
   PubMedGoogle Scholar
• Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 2009;124:170–8
   PubMed Web of Science ®Google Scholar
• Gums JG, Pelletier EM, Blumentals WA. Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother 2008;9:151–61
   PubMed Web of Science ®Google Scholar
• Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 2005;21:761–8
   PubMed Web of Science ®Google Scholar
• Loughlin JE, Alfredson TD, Ajene AN, et al. Risk for respiratory events in a cohort of patients receiving inhaled zanamivir: a retrospective study. Clin Ther 2002;24:1786–99
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (C.D.C.). “Have You Heard?” – CDC Recommendations for Influenza Antiviral Medications Remain Unchanged. 2011. http://www.cdc.gov/media/haveyouheard/stories/Influenza_antiviral2.html
   Google Scholar
• Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012;1:CD008965
   PubMed Web of Science ®Google Scholar
• Hansen LG, Chang S. Health Research Data for the Real World: The MarketScan Databases. The Truven Health Analytics, 2011
   Google Scholar
• Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60:1–24
   PubMedGoogle Scholar
• Uyeki T. Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1). N Engl J Med 2009;361:e110
   PubMed Web of Science ®Google Scholar
• Loughlin J, Poulios N, Napalkov P, et al. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics 2003;21:273–83
   PubMed Web of Science ®Google Scholar
• Meier CR, Napalkov PN, Wegmuller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000;19:834–42
   PubMed Web of Science ®Google Scholar
• Connolly AM, Salmon RL, Lervy B, Williams DH. What are the complications of influenza and can they be prevented – experience from the 1989 epidemic of H3n2 influenza-A in general-practice. Br Med J 1993;306:1452–4
   PubMed Web of Science ®Google Scholar
• Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ. Health outcomes among patients receiving oseltamivir. Pharmacoepidem Dr S 2004;13:227–37
   PubMed Web of Science ®Google Scholar
• Moses H, Matheson DH, Dorsey ER, et al. The anatomy of health care in the United States. JAMA 2013;310:1947–64
   PubMed Web of Science ®Google Scholar
• Zhang J, Kai FY. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:1690–1
   PubMed Web of Science ®Google Scholar
• Schmidt CO, Kohlmann T. When to use the odds ratio or the relative risk? Int J Publ Health 2008;53:165–7
   PubMed Web of Science ®Google Scholar
• Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702–6
   PubMed Web of Science ®Google Scholar
• Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1–3 years of age: a randomized controlled trial. Clin Infect Dis 2010;51:887–94
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Diaz E, Martin-Loeches I, et al. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother 2011;66:1140–9
   PubMed Web of Science ®Google Scholar
• Shi L, Loveless M, Spagnuolo P, et al. Antiviral treatment of influenza in children: a retrospective cohort study. Adv Ther 2014;31:735–50
   PubMed Web of Science ®Google Scholar
• Chan M, Lim PL, Chow A, et al. Surveillance for Clostridium difficile infection: ICD-9 coding haspoor sensitivity compared to laboratory diagnosis in hospital patients, Singapore. PLoS One 2011;6: e15603. doi: 10.1371/journal.pone.0015603
   Google Scholar
• Keren R, Wheeler A, Coffin SE, et al. ICD-9 codes for identifying influenza hospitalizations in children. Emerging Infect Dis 2006;12:1603–4
   PubMed Web of Science ®Google Scholar
• Feemster KA, Leckerman KH, Middleton M, et al. Use of administrative data for the identification of laboratory-confirmed influenza infection: the validity of influenza-specific ICD-9 Codes. J Pediatr Infect Dis Soc 2013;2:63–6
   PubMedGoogle Scholar
• Amodio E, Tramuto F, Costantino C, et al. Diagnosis of influenza: only a problem of coding? Med Princ Pract 2014;23:568–73
   PubMed Web of Science ®Google Scholar